Hemochron Signature Elite

Rapid assessment of direct oral anticoagulants in acute stroke-An educational systematic review.

Cardiopulmonary bypass in a pediatric patient with factor XII deficiency.

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban.

Warfarin Patients With Anemia Show Trend of Out-of-Range International Normalized Ratio Frequency With Point-of-Care Testing in an Anticoagulation Clinic.

Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs).

Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.

Activated Clotting Time Measured by Hemochron Signature Elite in Adult Cardiac Surgery: Implications for Clinical Practice.

Clinical Evaluation of the Heparin Therapeutic Window Using Activated Clotting Time in Neurological Interventional Radiology at an Academic Medical Center.

Thromboelastometry and two activated clotting tests in detecting residual heparin after protamine in cardiac surgical patients: A prospective cohort study.

Clinical monitoring of activated clotting time during cardiothoracic surgery: comparing the Hemochron® Response and Hemochron® Signature Elite.

Activated clotting time in inpatient diagnostic and interventional settings. [⇄ Hemochron Signature Elite]

A comparative analysis of four activated clotting time measurement devices in cardiac surgery with cardiopulmonary bypass.

Transition from Hemochron Response to Hemochron Signature Elite Activated Clotting Time Devices in a Congenital Cardiac Surgery Practice.

Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.

Intraoperative Monitoring of Heparin: Comparison of Activated Coagulation Time and Whole Blood Heparin Measurements by Different Point-of-Care Devices with Heparin Concentration by Laboratory-Performed Plasma Anti-Xa Assay.

Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution.

Performance of Hemochron ACT-LR and ACT+ Test Cuvettes in Monitoring Low to Moderate Heparin Concentrations: An In Vitro Study.

Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO).

Thrombolysis in stroke patients: Comparability of point-of-care versus central laboratory international normalized ratio.

Evaluation of point-of-care testing in critically unwell patients: comparison with clinical laboratory analysers and applicability to patients with Ebolavirus infection.

Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite(R) during acute haemorrhage.